121 related articles for article (PubMed ID: 14582451)
1. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases.
Jeng AY
Curr Opin Investig Drugs; 2003 Sep; 4(9):1076-81. PubMed ID: 14582451
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications.
Jeng AY; Mulder P; Kwan AL; Battistini B
Can J Physiol Pharmacol; 2002 May; 80(5):440-9. PubMed ID: 12056551
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
Doggrell SA
Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501
[TBL] [Abstract][Full Text] [Related]
4. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
Lin CL; Winardi W; Jeng AY; Kwan AL
Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
[TBL] [Abstract][Full Text] [Related]
5. Structure of human endothelin-converting enzyme I complexed with phosphoramidon.
Schulz H; Dale GE; Karimi-Nejad Y; Oefner C
J Mol Biol; 2009 Jan; 385(1):178-87. PubMed ID: 18992253
[TBL] [Abstract][Full Text] [Related]
6. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Jeng AY; Savage P; Beil ME; Bruseo CW; Hoyer D; Fink CA; Trapani AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
[TBL] [Abstract][Full Text] [Related]
8. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
Daull P; Jeng AY; Battistini B
J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
Kuruppu S; Rajapakse NW; Smith AI
Pflugers Arch; 2013 Jul; 465(7):929-34. PubMed ID: 23328864
[TBL] [Abstract][Full Text] [Related]
10. Novel selective quinazoline inhibitors of endothelin converting enzyme-1.
Ahn K; Sisneros AM; Herman SB; Pan SM; Hupe D; Lee C; Nikam S; Cheng XM; Doherty AM; Schroeder RL; Haleen SJ; Kaw S; Emoto N; Yanagisawa M
Biochem Biophys Res Commun; 1998 Feb; 243(1):184-90. PubMed ID: 9473502
[TBL] [Abstract][Full Text] [Related]
11. In-silico characterization of ECE-1 inhibitors.
Ajay Babu P; Colluru VT; Anaparthy N
Comput Biol Med; 2012 Apr; 42(4):446-57. PubMed ID: 22245098
[TBL] [Abstract][Full Text] [Related]
12. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs.
Lüscher TF; Barton M
Circulation; 2000 Nov; 102(19):2434-40. PubMed ID: 11067800
[TBL] [Abstract][Full Text] [Related]
13. Multitarget cardiovascular drugs.
Trstenjak U; Kikelj D
Curr Med Chem; 2011; 18(17):2531-42. PubMed ID: 21568894
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and degradation of endothelin-1.
D'Orléans-Juste P; Plante M; Honoré JC; Carrier E; Labonté J
Can J Physiol Pharmacol; 2003 Jun; 81(6):503-10. PubMed ID: 12839262
[TBL] [Abstract][Full Text] [Related]
15. Endothelins are potent vasoconstrictors, and much more besides.
Gray GA; Battistini B; Webb DJ
Trends Pharmacol Sci; 2000 Feb; 21(2):38-40. PubMed ID: 10733432
[No Abstract] [Full Text] [Related]
16. Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases.
Cerdeira AS; Brás-Silva C; Leite-Moreira AF
Rev Port Cardiol; 2008 Mar; 27(3):385-408. PubMed ID: 18551924
[TBL] [Abstract][Full Text] [Related]
17. Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
Rabelink TJ; Stroes ES; Bouter KP; Morrison P
Cardiovasc Res; 1998 Sep; 39(3):543-9. PubMed ID: 9861295
[No Abstract] [Full Text] [Related]
18. Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.
Brands M; Ergüden JK; Hashimoto K; Heimbach D; Krahn T; Schröder C; Siegel S; Stasch JP; Tsujishita H; Weigand S; Yoshida NH
ChemMedChem; 2006 Jan; 1(1):96-105. PubMed ID: 16892341
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the pharmacological effects of endothelin.
Wilson C; Hargreaves RB
Prog Med Chem; 1994; 31():371-410. PubMed ID: 8029479
[No Abstract] [Full Text] [Related]
20. Endothelin-converting enzyme inhibitors: current status and perspectives.
Löffler BM
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S79-82. PubMed ID: 10976788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
